Burns Grace L, Hoedt Emily C, Walker Marjorie M, Talley Nicholas J, Keely Simon
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW, Australia.
NHMRC Centre for Research Excellence in Digestive Health, University of Newcastle, Newcastle, NSW, Australia.
J Physiol. 2021 Dec;599(23):5141-5161. doi: 10.1113/JP281620. Epub 2021 Nov 12.
Functional gastrointestinal disorders (FGIDs) encompass a range of complex conditions with similar clinical characteristics and no overt pathology. Recent recognition of sub-clinical pathologies in FGIDs, in conjunction with physiological and biochemical abnormalities including increased intestinal permeability, microbial profile alterations, differences in metabolites and extra-intestinal manifestations of disease, call into question the designation of these conditions as 'functional'. This is despite significant heterogeneity in both symptom profile and specifics of reported physiological abnormalities hampering efforts to determine defined mechanisms that drive onset and chronicity of symptoms. Instead, the literature demonstrates these conditions are disorders of homeostatic imbalance, with disruptions in both host and microbial function and metabolism. This imbalance is also associated with extraintestinal abnormalities including psychological comorbidities and fatigue that may be a consequence of gastrointestinal disruption. Given the exploitation of such abnormalities will be crucial for improved therapeutic selection, an enhanced understanding of the relationship between alterations in function of the gastrointestinal tract and the response of the immune system is of interest in identifying mechanisms that drive FGID onset and chronicity. Considerations for future research should include the role of sex hormones in regulating physiological functions and treatment responses in patients, as well as the importance of high-level phenotyping of clinical, immune, microbial and physiological parameters in study cohorts. There is opportunity to examine the functional contribution of the microbiota and associated metabolites as a source of mechanistic insight and targets for therapeutic modulation.
功能性胃肠疾病(FGIDs)包括一系列具有相似临床特征且无明显病理学改变的复杂病症。近期对FGIDs亚临床病理学的认识,连同生理和生化异常,包括肠道通透性增加、微生物谱改变、代谢物差异以及疾病的肠外表现,使这些病症被归类为“功能性”受到质疑。尽管症状谱和所报告的生理异常细节存在显著异质性,这阻碍了确定驱动症状发作和慢性化的明确机制的努力。相反,文献表明这些病症是稳态失衡的疾病,宿主和微生物的功能及代谢均受到破坏。这种失衡还与肠外异常有关,包括心理共病和疲劳,这些可能是胃肠道紊乱的结果。鉴于利用此类异常对于改善治疗选择至关重要,深入了解胃肠道功能改变与免疫系统反应之间的关系,对于确定驱动FGID发作和慢性化的机制很有意义。未来研究的考虑因素应包括性激素在调节患者生理功能和治疗反应中的作用,以及临床、免疫、微生物和生理参数的高级别表型分析在研究队列中的重要性。有机会研究微生物群及其相关代谢物的功能贡献,作为机制洞察的来源和治疗调节的靶点。